Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Covigenix VAX-002
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Entos Pharmaceuticals Doses First Participant in COVID-19 Vaccine Booster Trial
Details : Entos investigational product Covigenix VAX-002 is a plasmid DNA vaccine, which is being evaluated in the Phase 1/2 clinical trial studies to treat COVID-19.
Brand Name : Covigenix VAX-002
Molecule Type : Vaccine
Upfront Cash : Not Applicable
August 06, 2024
Lead Product(s) : Covigenix VAX-002
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Covigenix VAX-002
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Entos Gets Approval to Begin Clinical Trial for COVID-19 Vaccine Booster
Details : Entos investigational product Covigenix VAX-002 is a plasmid DNA vaccine, which is being evaluated in the Phase 1/2 clinical trial studies to treat COVID-19.
Brand Name : Covigenix VAX-002
Molecule Type : Vaccine
Upfront Cash : Not Applicable
June 10, 2024
Lead Product(s) : Covigenix VAX-002
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Alberta Cancer Foundation
Deal Size : $0.1 million
Deal Type : Funding
Alberta Cancer Foundation Invests in Early-Stage Cancer Research Fund
Details : The funding will aid Entos in advancing personalized immunotherapy strategies utilizing DNA vaccines tailored to target mutations in patients' tumors for treating advanced cancer.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
January 23, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Alberta Cancer Foundation
Deal Size : $0.1 million
Deal Type : Funding
Lead Product(s) : Nucleic acid-based Therapies
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Eli Lilly
Deal Size : $450.0 million
Deal Type : Collaboration
Details : Under the terms of the research and collaboration agreement, Lilly and Entos have agreed to multiple programs focused on the development of proteo-lipid vehicles (PLV) for delivery of therapeutic cargo supplied by Lilly to targets in the central and peri...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $50.0 million
January 06, 2022
Lead Product(s) : Nucleic acid-based Therapies
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Eli Lilly
Deal Size : $450.0 million
Deal Type : Collaboration
Lead Product(s) : Fusogenix-formulated Gene Therapy
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : BioMarin Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Entos will use its Fusogenix nucleic acid delivery system to specially formulate BioMarin products directed at multiple undisclosed genetic disease indications.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 15, 2021
Lead Product(s) : Fusogenix-formulated Gene Therapy
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : BioMarin Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Covigenix
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : NRC IRAP
Deal Size : $5.0 million
Deal Type : Funding
Entos Pharmaceuticals Awarded Funding to Conduct Phase I Clinical Trial of COVID-19 DNA Vaccine
Details : Entos developed a Fusogenix DNA vaccine called Covigenix, that in preclinical studies, induces a strong neutralizing antibody response plus a potent and balanced T cell response against SARS-CoV-2, the virus that causes COVID-19.
Brand Name : Covigenix
Molecule Type : Vaccine
Upfront Cash : Undisclosed
October 23, 2020
Lead Product(s) : Covigenix
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : NRC IRAP
Deal Size : $5.0 million
Deal Type : Funding
Lead Product(s) : Fusogenix DNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Canadian Institutes of Health Research (CIHR)
Deal Size : $4.2 million
Deal Type : Funding
Details : Company announced the selection of two lead candidates for a pan-coronavirus Fusogenix DNA vaccine (Covigenix) from its prototyping program launched at the onset of the global COVID-19 pandemic.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
June 25, 2020
Lead Product(s) : Fusogenix DNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Canadian Institutes of Health Research (CIHR)
Deal Size : $4.2 million
Deal Type : Funding
Lead Product(s) : Covigenix
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : GE Healthcare Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Cytiva and Entos Pharmaceuticals work together to accelerate development of COVID19 vaccines
Details : Cytiva’s Fast Trak process development team will use their expertise to develop a scalable downstream protein purification method that will enable GMP-production of the Fusogenix protein component that facilitates intracellular DNA delivery.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
June 01, 2020
Lead Product(s) : Covigenix
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : GE Healthcare Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Fusogenix
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : EpiVax
Deal Size : Undisclosed
Deal Type : Partnership
Epivax and Entos Pharmaceuticals to develop DNA-based vaccine for COVID-19
Details : This partnership will combine the Entos Fusogenix DNA delivery technology with optimized COVID-19 epitopes from EpiVax to generate a highly effective immune response against the novel coronavirus.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
April 28, 2020
Lead Product(s) : Fusogenix
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : EpiVax
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Fusogenix DNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The vaccine payload will be plasmid DNA encoding multiple antigens from key SARS-CoV-2 proteins to promote maximum protection.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
March 18, 2020
Lead Product(s) : Fusogenix DNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?